Copper Tripeptide-1
A copper-bound peptide the body makes naturally, used on skin to support its own repair signalling.
Peer-reviewed randomized double-blind trial data on facial wrinkle parameters, on top of extensive laboratory and wound-healing literature. Trial results across the literature are mixed.
On the label: Copper Tripeptide-1. Also known as Copper peptide, Copper peptides, Glycyl-L-histidyl-L-lysine copper.
What it does for you
Supports firmer, more even-looking skin on a timeline of months rather than days. Because it works with a signal your skin already recognises rather than forcing a reaction, most people tolerate it well.
Why we use it
It is the Signal in Signal and Structure. We chose a molecule skin already knows over an irritant that forces a response, because that is what makes one daily active sustainable instead of something you cycle on and off. In a peer-reviewed, randomized double-blind clinical trial published in the Journal of Aging Science (Badenhorst et al., 2016), topical Copper Tripeptide-1 produced a 55.8% reduction in visible wrinkle volume and 32.8% reduction in wrinkle depth compared to untreated control skin over 8 weeks — and delivered 31.6% greater wrinkle volume reduction than a Matrixyl® 3000-only formula. That's why VitalCopper pairs both. In a separate pilot clinical study comparing topical actives directly, Copper Tripeptide-1 showed improved procollagen synthesis in 70% of subjects — vs. 50% for Vitamin C and 40% for tretinoin. Abdulghani et al. (1998), Disease Management and Clinical Outcomes.
Mechanism
The peptide binds copper and carries it into cells. Copper is the cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, and in laboratory studies Copper Tripeptide-1 raises production of collagen and other matrix components. In laboratory studies it also raises both the enzymes that break matrix down and the inhibitors that regulate them. Researchers read that as active remodelling: clearing degraded matrix rather than layering new collagen on top of old. That is renewal in the literal sense, and it is slower and less dramatic than it sounds. Copper Tripeptide-1 is a naturally occurring copper-bound peptide, the same repair signal your skin produces in response to aging and uses to regulate tissue remodeling. Research interest spans over 50 years of published literature covering collagen and elastin biology, gene expression, and wound healing.
Use level
1% Copper Tripeptide-1 solution in VitalCopper Renewal Face Serum, used at 20% of formula for 0.20% pure Copper Tripeptide-1 (2,000 ppm). Disclosed in full, because most percentage claims in this category don't say whether they mean pure peptide, a diluted solution, or a share of a blend. That 20% inclusion sits at the top of the treatment tier this ingredient's own supplier publishes, four times the ceiling of what the same document calls daily-care dosing. The dose was set first. The formula was built around it.
Commonly confused with
Most people say copper peptide, and in skincare that almost always means this one: Copper Tripeptide-1 is the ingredient-list name, and glycyl-L-histidyl-L-lysine copper is the full chemical name for the same molecule. It is not elemental copper, the dietary mineral. We use both across our range: trace copper in VitalBuild Daily Collagen Powder as a nutrient, and this copper peptide on skin. Different things, different jobs. It is also not a copper salt such as copper gluconate or copper PCA. Those deliver copper but are not peptides. Other copper peptides exist. AHK-Cu is the one you are most likely to meet, and it is studied mainly for hair rather than skin. Research on one copper peptide does not automatically apply to another, which is why we name the exact peptide rather than saying copper peptides.
What the studies say
Facial wrinkle volume reduced 55.8% versus the vehicle-only serum and 31.6% versus the Matrixyl 3000 formula; wrinkle depth reduced 32.8% versus vehicle. Parallel in vitro experiments reported increased collagen and elastin production and a favourable shift in the MMP/TIMP balance. This is the peer-reviewed source for the 55.8% figure used on the VitalCopper product page.
- Human in vivo (topical), peer-reviewed
- n = 40 women aged 40-65
- 8 weeks
Randomized, double-blind; copper tripeptide in a lipid nano-carrier vs. a Matrixyl 3000 formula vs. vehicle-only serum, with parallel in vitro work on MMP/TIMP expression
Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Journal of Aging Science, 2016. DOI 10.4172/2329-8847.1000166
Published in the Journal of Aging Science (OMICS / Walsh Medical Media), an open-access publisher whose editorial standards have been questioned; weigh the peer-review claim accordingly. Note the comparators were a vehicle serum and a Matrixyl 3000 formula - this trial does not compare against vitamin C or retinol, so it does not substantiate that comparison on its own.
Improved procollagen synthesis was observed in 70% of subjects using the copper-binding peptide cream, compared with 50% for vitamin C and 40% for tretinoin. This is the source for the comparative claim that the copper peptide outperformed vitamin C and retinoic acid on the VitalCopper product page.
- Human in vivo (topical), pilot
Pilot clinical, histologic and ultrastructural comparison of four topical creams on normal skin: vitamin C, a copper-binding peptide, melatonin, and tretinoin
Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin - a pilot clinical, histologic and ultrastructural study Abdulghani AA, Sherr A, Shirin S, et al.. Disease Management and Clinical Outcomes, 1998. DOI 10.1016/s1088-3371(98)00011-4
A pilot study. The endpoint is procollagen synthesis measured at the ultrastructural level, not visible wrinkle outcome, so it supports a mechanism-level comparison rather than a cosmetic-outcome comparison. Sample size is small and the journal was short-lived, which limits how much weight the percentages carry. Note the comparator was tretinoin (prescription retinoic acid), not cosmetic retinol - the two are not interchangeable.
Found no statistically significant difference on objective measures of erythema resolution, wrinkle improvement or overall skin quality. Only the patient self-report questionnaire favoured the copper peptide (P = .04). This is the most rigorous published human facial study of Copper Tripeptide-1 and it is null on objective endpoints.
- Human in vivo
- n = 13 completed
- 12 weeks
Randomized, blinded-evaluator, computer-assisted image analysis
Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin Miller TR, Wagner JD, Baack BR, Eisbach KJ. Archives of Facial Plastic Surgery, 2006. DOI 10.1001/archfaci.8.4.252
Independent academic study.
States there is a surprising absence of clinical studies for the topical peptide, with and without copper, despite market ubiquity. Also flags two formulation problems: the peptide is hydrophilic with a low lipid partition coefficient so skin permeation is poor, and it is unstable in formulation.
- Review
Topically applied glycyl-L-histidyl-L-lysine as an anti-wrinkle peptide: Advantages, problems and prospective Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. BioImpacts, 2025. DOI 10.34172/bi.30071
Independent review. Note that many circulating copper peptide reviews are authored by the peptide's commercial developer and should be treated as narrative, not independent evidence.
Stimulation of collagen synthesis began between 10^-12 and 10^-11 M, maximised at 10^-9 M, and was independent of any change in cell number. The peptide is not producing more cells; existing fibroblasts produce more.
- In vitro
Fibroblast culture, dose-response
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. FEBS Letters, 1988. DOI 10.1016/0014-5793(88)80509-x
Loren Pickart is a co-author. Unlike his later self-authored reviews, this is a 1988 primary paper in a mainstream journal with five other authors, so it is usable as evidence rather than as an interested-party summary.
GHK-Cu increased MMP-2 levels and MMP-2 mRNA, and also increased secretion of the inhibitors TIMP-1 and TIMP-2. The authors conclude it activates remodelling of the extracellular matrix, not only production of connective tissue.
- In vitro
Dermal fibroblast culture
The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures Simeon A, Emonard H, Hornebeck W, Maquart FX. Life Sciences, 2000. DOI 10.1016/s0024-3205(00)00803-1
Worth recording: the MMP-2 effect was reproduced by copper ions but not by the tripeptide GHK alone. This does not undermine a claim made about the GHK-Cu complex, but it is the nuance a critic would raise first.
The copper peptide gel achieved 98.5% versus 60.8% median area closure of diabetic neuropathic ulcers, with lower infection incidence (7% versus 34%). This is the wound-healing literature from which cosmetic claims are extrapolated. It is not a cosmetic endpoint.
- Human in vivo (wound healing, not cosmetic)
Randomized, placebo-controlled
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Wound Repair and Regeneration, 1994. DOI 10.1046/j.1524-475X.1994.20406.x
Sample size not stated in the abstract.
Panel concluded the ingredient family is safe at present practices of use and concentration. Reports concentration-of-use ranges: Tripeptide-1 at 0.00002 to 0.001 percent; Palmitoyl Tripeptide-1 at 0.0000001 to 0.001 percent; Palmitoyl Tetrapeptide-7 at 0.000005 to 0.0015 percent across 249 reported uses.
- Regulatory safety review
Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics Johnson W Jr, Bergfeld WF, Belsito DV, et al. (Cosmetic Ingredient Review Expert Panel). International Journal of Toxicology, 2018. DOI 10.1177/1091581818807863
Industry-funded expert panel, but the standard safety reference for cosmetic ingredients.
Who should be cautious
Copper-handling disorders such as Wilson's disease. Separate from strong direct acids by timing.